Purpose of Review <p>This article summarizes the clinical effects of incretin therapies. We review data from recent clinical trials, beyond glycemic control and weight reduction.</p> Recent Findings <p>Incretin therapies are associated with a lower risk of atherosclerotic cardiovascular events and improved clinical outcomes in patients with heart failure and preserved ejection fraction. Recent studies demonstrate a much wider spectrum of clinical benefits, including nephroprotection in patients with diabetic kidney disease, diabetes prevention, therapeutic potential in the management of metabolic dysfunction-associated steatotic liver disease and obstructive sleep apnea, and even neuroprotective effects. Possible adverse events, primarily involving the gastrointestinal system, and the need for long-term continuation are factors that need to be considered before initiation of treatment.</p> Summary <p>Incretin receptor agonists have changed the landscape of diabetes and obesity management. Their clinical benefits expand to a wide spectrum of cardiovascular and metabolic disorders and have major implications for clinical practice.</p>